1
|
Oka D, Changkwanyeun R, Yamaguchi T, Nakajima C, Suzuki Y, Matsumoto M. In vitro antibacterial activity of OPS-2071 against Gram-positive and Gram-negative enteropathogenic bacteria. J Antimicrob Chemother 2022; 77:3248-3255. [PMID: 36101508 DOI: 10.1093/jac/dkac308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Accepted: 08/18/2022] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Enteric infections are a major public health issue in developing countries. Antimicrobial resistance is also a problem for enteric infection. OPS-2071 is a novel quinolone antibiotic with low oral absorption and potent antibacterial activity against Clostridioides difficile. OBJECTIVES This study was conducted to confirm the antimicrobial activity of OPS-2071 against major enteropathogenic bacteria and to evaluate the risk of emergence of drug resistance. METHODS The antibacterial activity was evaluated by the agar dilution method. The inhibitory activity against DNA gyrase and topoisomerase IV was determined by supercoiling assay and decatenation assay, respectively. The mutant prevention concentration and frequency of spontaneous resistance were determined by inoculation on drug-containing agar. RESULTS Compared with the reference drugs, the antibacterial activity of OPS-2071 was more potent against Gram-positive bacteria and Campylobacter jejuni, including quinolone-resistant strains. Against other Gram-negative bacteria, OPS-2071 was comparable to existing quinolones. The inhibitory activities against DNA gyrase with quinolone-resistant mutations closely correlated with the antibacterial activity. Spontaneous resistance to OPS-2071 was not observed in Staphylococcus aureus and Escherichia coli and was lower than that of existing quinolones and higher than that of azithromycin in C. jejuni. The mutant prevention concentration of OPS-2071 was lower than that of tested compounds in S. aureus and C. jejuni and slightly higher than that of existing quinolones in E. coli. CONCLUSIONS The broad and potent in vitro antibacterial activity and lower risk of drug resistance suggested that OPS-2071 may be useful for enteric infections caused by major pathogens including quinolone-resistant Campylobacter.
Collapse
Affiliation(s)
- Daisuke Oka
- Department of Medical Innovations, New Drug Research Division, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan
| | - Ruchirada Changkwanyeun
- Division of Bioresources, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan
| | - Tomoyuki Yamaguchi
- Division of Bioresources, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan
| | - Chie Nakajima
- Division of Bioresources, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.,International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan
| | - Yasuhiko Suzuki
- Division of Bioresources, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.,International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan
| | - Makoto Matsumoto
- Pharmaceutical Business Division, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan
| |
Collapse
|
2
|
González-Villarreal JA, González-Lozano KJ, Aréchiga-Carvajal ET, Morlett-Chávez JA, Luévanos-Escareño MP, Balagurusamy N, Salinas-Santander MA. Molecular mechanisms of multidrug resistance in clinically relevant enteropathogenic bacteria (Review). Exp Ther Med 2022; 24:753. [PMID: 36561977 PMCID: PMC9748766 DOI: 10.3892/etm.2022.11689] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2022] [Accepted: 09/21/2022] [Indexed: 11/11/2022] Open
Abstract
Multidrug resistant (MDR) enteropathogenic bacteria are a growing problem within the clinical environment due to their acquired tolerance to a wide range of antibiotics, thus causing severe illnesses and a tremendous economic impact in the healthcare sector. Due to its difficult treatment, knowledge and understanding of the molecular mechanisms that confer this resistance are needed. The aim of the present review is to describe the mechanisms of antibiotic resistance from a genomic perspective observed in bacteria, including naturally acquired resistance. The present review also discusses common pharmacological and alternative treatments used in cases of infection caused by MDR bacteria, thus covering necessary information for the development of novel antimicrobials and adjuvant molecules inhibiting bacterial proliferation.
Collapse
Affiliation(s)
| | - Katia Jamileth González-Lozano
- Microbiology Department, Phytopathology and Mycology Laboratory, Faculty of Biological Sciences, Genetic Manipulation Unit, Autonomous University of Nuevo Leon, Monterrey, Nuevo León 66459, Mexico
| | - Elva Teresa Aréchiga-Carvajal
- Microbiology Department, Phytopathology and Mycology Laboratory, Faculty of Biological Sciences, Genetic Manipulation Unit, Autonomous University of Nuevo Leon, Monterrey, Nuevo León 66459, Mexico
| | - Jesús Antonio Morlett-Chávez
- Research Department, Faculty of Medicine Saltillo Unit, Autonomous University of Coahuila, Saltillo, Coahuila 25000, Mexico
| | | | - Nagamani Balagurusamy
- Bioremediation Laboratory, Faculty of Biological Sciences, Autonomous University of Coahuila, Torreón, Coahuila 27275, Mexico
| | - Mauricio Andrés Salinas-Santander
- Research Department, Faculty of Medicine Saltillo Unit, Autonomous University of Coahuila, Saltillo, Coahuila 25000, Mexico,Correspondence to: Dr Mauricio Andrés Salinas-Santander, Research Department, Faculty of Medicine Saltillo Unit, Autonomous University of Coahuila, Calle Francisco Murguía Sur 205, Zona Centro, Saltillo, Coahuila 25000, Mexico
| |
Collapse
|
3
|
Antibiotic properties of Satureja montana L. hydrolate in bacteria and fungus of clinical interest and its impact in non-target environmental microorganisms. Sci Rep 2022; 12:18460. [PMID: 36323748 PMCID: PMC9630514 DOI: 10.1038/s41598-022-22419-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2022] [Accepted: 10/14/2022] [Indexed: 11/20/2022] Open
Abstract
The aim of this study was to analyse the microbicidal and microbiostatic activity of S. montana hydrolate L., the water-soluble fraction of the hydro-distillation process used to obtain the essential oil, on 14 Gram-positive and Gram-negative bacteria and a fungus of clinical interest. To consider whether this hydrolate is a more environmentally friendly alternative to traditional antibiotics, its effect on non-target microorganisms in the aquatic and terrestrial environment was analysed using natural soil and river microorganism communities, characterized through 16S rRNA gene sequencing. Results showed that S. montana hydrolate was especially effective (25% v/v concentration) against Pasteurella aerogenes, Streptococcus agalactiae and Acinetobacter baumannii (priority 1, WHO). It was also a microbicide for a further 7 bacterial strains and the fungus Candida albicans (50% v/v concentration). The river and soil communities exposed to the hydrolate showed a decrease in their growth, as well as a decrease in their ability to metabolize polymers and carbohydrates (soil microorganisms) and polymers, carboxylic and ketone acids (river microorganisms). Hydrolates could be an alternative to conventional antibiotics, but their impact on the environment must be taken into account.
Collapse
|
4
|
Gonzales JC, Seribelli AA, Gomes CN, Dos Prazeres Rodrigues D, Campioni F, Passaglia J, da Silva P, Falcão JP. A high number of multidrug-resistant and predominant genetically related cluster of Shigella flexneri strains isolated over 34 years in Brazil. Braz J Microbiol 2020; 51:1563-1571. [PMID: 32710175 DOI: 10.1007/s42770-020-00332-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2019] [Accepted: 06/29/2020] [Indexed: 11/26/2022] Open
Abstract
Shigella flexneri has been a major public health problem in developing countries. This work analyzed the frequency of 16 virulence genes, the genotypic diversity, and the antimicrobial resistance profiles of 130 S. flexneri strains isolated in Brazil. The ipaH gene was found in all the 130 strains. The frequencies of the other genes were variable ial (88.5%), sigA (82.3%), iuc (74.6%), virA (73%), pic (72.3%), virF (57.7%), sat (48.5%), ipaBCD (37%), sen (36%), set1A (35.4%), sepA (30%), set1B (30%), virB (14%), icsA (10%), and ipgD (5.4%). A total of 57 (43.8%) strains were multidrug-resistant. ERIC-PCR grouped 96 of the strains into a single cluster with ≥ 70.4% of similarity, 75 of these strains presented a similarity ≥ 80.9%. PFGE grouped 120 of the strains into a single cluster with 57.4% of similarity and 82 of these strains presented a similarity ≥ 70.6%. In conclusion, the high frequency of some virulence genes reinforces the pathogenic potential of the strains studied. The high rates of MDR strains are alarming once it may lead to failure when antimicrobial treatment is necessary. Genotype techniques reveled a major cluster with high genetic similarity including S. flexneri strains from the different Brazilian states and distinct years of isolation, showing that they probably emerged from a common ancestor.
Collapse
Affiliation(s)
- Júlia Cunha Gonzales
- Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo-USP, Av. do Café, s/no-Campus Universitário USP, Ribeirão Preto, SP, 14040-903, Brazil
| | - Amanda Aparecida Seribelli
- Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo-USP, Av. do Café, s/no-Campus Universitário USP, Ribeirão Preto, SP, 14040-903, Brazil
| | - Carolina Nogueira Gomes
- Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo-USP, Av. do Café, s/no-Campus Universitário USP, Ribeirão Preto, SP, 14040-903, Brazil
| | | | - Fábio Campioni
- Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo-USP, Av. do Café, s/no-Campus Universitário USP, Ribeirão Preto, SP, 14040-903, Brazil
| | - Jaqueline Passaglia
- Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo-USP, Av. do Café, s/no-Campus Universitário USP, Ribeirão Preto, SP, 14040-903, Brazil
| | - Paulo da Silva
- Instituto Adolfo Lutz de Ribeirão Preto, São Paulo, Brazil
| | - Juliana Pfrimer Falcão
- Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo-USP, Av. do Café, s/no-Campus Universitário USP, Ribeirão Preto, SP, 14040-903, Brazil.
| |
Collapse
|